Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 9,801–9,900 of 15,747
Vaccination and COVID-19: impact on long-COVID
Guimarães, G. N., Brunetti, N. S., de Lima, D. G., Proença‐Módena, J. L., & Farias, A. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1686572 · Cited by 9
Jerbi, A. (2025) · SIMULATION · doi:10.1177/00375497241308563 · Cited by 4
Unilateral blaschkoid lichen planus successfully treated with upadacitinib
Rosenbaum, C., Tan, V. T., Grekin, J. A., et al. (2024) · JAAD Case Reports · doi:10.1016/j.jdcr.2024.01.007 · Cited by 4
Wang, Y., Zheng, X., Liu, J., Chen, L., Chen, Q., & Zhao, Y. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2022.05.006 · Cited by 4
Vaccination against COVID-19 in a haemodialysis centre: what is the risk of bleeding complications?
Giot, M., Robert, T., Brunet, P., Resseguier, N., & Lano, G. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab059 · Cited by 4
The Hair and Scalp in Systemic Infectious Disease
Trüeb, R. M., Dias, M. F. R. G., Rezende, H. D., Vilte, R. M. D. L. C. V., & Romiti, R. (2023) · Springer eBooks · doi:10.1007/978-3-031-30754-6_10 · Cited by 6
Barroso‐Arévalo, S., Sánchez‐Morales, L., Domínguez, M., García‐Seco, T., Risalde, M. Á., García‐Bocanegra, I., Domı́nguez, L., & Sánchez‐Vizcaíno, J. M. (2022) · Research in Veterinary Science · doi:10.1016/j.rvsc.2022.05.003 · Cited by 4
Qureshi, A., & Connolly, J. B. (2023) · Malaria Journal · doi:10.1186/s12936-023-04665-5 · Cited by 5
“However, human intradermal and intramuscular exposure to RNA from therapeutic interventions such as mRNA-based vaccinations against COVID-19 have a proven safety profile for use in humans [191–193].”
BackgroundGung, C., McGuire, R., George, M., Abdulkareem, A., Belden, K. A., Porcu, P., Martinez‐Outschoorn, U., Binder, A. F., Chervenova, I., & Alpdoğan, Ö. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.840451 · Cited by 5
“The BNT162b2 (Pfizer/BioNTech) and the mRNA-1273 (Moderna) Covid-19 vaccines have both been shown in large phase III clinical trials to be more than 90 percent effective at preventing lab-confirmed Covid-19 illness and severe infections (1, 2).”
BackgroundČiučiulkaitė, I., Siffert, W., Elsner, C., Dittmer, U., Wichert, M., Wagner, B., Volbracht, L., Mosel, F., & Möhlendick, B. (2023) · Vaccines · doi:10.3390/vaccines11071257 · Cited by 6
Karaliota, S., Moussa, M., Rosati, M., Devasundaram, S., Sengupta, S., Goldfarbmuren, K. C., Burns, R., Bear, J., Stellas, D., Urban, E., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112232 · Cited by 4
Manifestaciones neurológicas asociadas a la vacuna contra COVID-19
Castillo, R. A., & Martínez‐Castrillo, J. C. (2022) · Neurología · doi:10.1016/j.nrl.2022.09.005 · Cited by 4
SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants
Syahniar, R., & Kharisma, D. S. (2022) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2022.11.2.173 · Cited by 6
“BNT162b2 (PfizerBioNTech) mRNA 95% after second dose [35] 93.”
BackgroundMethodMonin, M. B., Gorny, J. G., Berger, M., Baier, L. I., Zhou, T., Mahn, R., Sadeghlar, F., Möhring, C., Boesecke, C., van Bremen, K., et al. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-1065 · Cited by 3
“However, actively treated patients with cancer were excluded from trials analyzing efficacy of SARS-CoV-2 vaccines (5-9).”
Proposals to Accelerate Novel Vaccine Development for Children
Permar, S. R., Creech, C. B., Edwards, K. M., & Walter, E. B. (2021) · PEDIATRICS · doi:10.1542/peds.2021-054593 · Cited by 4
Takano, T., Sato, T., Kotaki, R., Moriyama, S., Shinoda, M., Kabasawa, K., Shimada, N., Kousaka, M., Adachi, Y., Onodera, T., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2014078/v1 · Cited by 4
Neutralization of VOCs including Delta one year post COVID-19 or vaccinePreprint
Havervall, S., Marking, U. W., Gordon, M., Ng, H., Greilert‐Norin, N., Lindbo, S., Blom, K. G., Nilsson, P., Phillipson, M., Klingström, J., et al. (2021) · medRxiv · doi:10.1101/2021.08.12.21261951 · Cited by 4
The Regulation of Nucleic Acid Vaccine Responses by the Microbiome
Johnson, A. M. F., Hager, K., Alameh, M., Van, P., Potchen, N. B., Mayer-Blackwell, K., Fiore-Gartland, A. J., Minot, S. S., Lin, P. J. C., Tam, Y. K., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300196 · Cited by 6
Thirión-Romero, I. I., Plata, R. F., Pérez-Kawabe, M., Meza-Meneses, P. A., Castro-Fuentes, C. A., Rivera-Martínez, N. E., Barrón-Palma, E. V., Sánchez-Sandoval, A. L., Cornejo‐Juárez, P., Sepúlveda-Delgado, J., et al. (2023) · Vaccines · doi:10.3390/vaccines11121779 · Cited by 4
Higher COVID-19 vaccination rates are linked to decreased county-level COVID-19 incidence across USAPreprint
Puranik, A., Venkatakrishnan, A., Pawlowski, C., Raghunathan, B., Ramudu, E., Lenehan, P. J., Agarwal, V., Jayaram, S., Choudhary, M., & Soundararajan, V. (2021) · medRxiv · doi:10.1101/2021.03.05.21252946 · Cited by 5
Ladak, K., Winthrop, K. L., Marshall, J. K., Gelfand, J. M., & Pope, J. E. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/9ysvg3 · Cited by 5
Titus, T., & Rahman, A. (2021) · Australian Journal of General Practice · doi:10.31128/ajgp-12-20-5764 · Cited by 4
Hirotsu, Y., Sugiura, H., Takatori, M., Mochizuki, H., & Omata, M. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01316-23 · Cited by 5
Yogesh, R., Srivastava, N., & Bukhari, S. N. A. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220701160116 · Cited by 5
New-onset aplastic anemia after SARS-CoV-2 vaccination
Chatzikalil, E., Kattamis, A., Diamantopoulos, P. T., & Solomou, E. E. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03666-z · Cited by 4
“There are a few case reports describing new onset or worsening AA shortly after vaccination, [13–16, 27, 32].”
BackgroundJitsuk, N. C., Chadsuthi, S., & Modchang, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28042 · Cited by 5
“(2) (see Supplementary Information for more details). e D and e S are the vaccine effectiveness against symptomatic disease and infection, respectively [34 – 37].”
BackgroundHossaini, S., Keramat, F., Cheraghi, Z., Zareie, B., & Doosti‐Irani, A. (2023) · Journal of Research in Health Sciences · doi:10.34172/jrhs.2023.128 · Cited by 6
Alnemari, R. F., Roublah, F. A., & Bargawi, A. A. (2023) · Cureus · doi:10.7759/cureus.41067 · Cited by 8
“High levels of protection (over 90%) are also seen against mortality with three types of vaccines and against both the Alpha and Delta variants in many other studies [23-25].”
BackgroundNanostrategies to Develop Current Antiviral Vaccines
Rodrigues, G. R., Sousa, M. G. D. C., da Silva, D. C., Rezende, T. M. B., Morais, P. C., & Franco, O. L. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01284 · Cited by 4
Jabal, K. A., Ben-Amram, H., Wiegler, K. B., Brimat, I., Saada, A. A., Bathish, Y., Sussan, C., Zarka, S., & Edelstein, M. L. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821001928 · Cited by 4
“Vaccine efficacy from a single dose of the BNT162b2 vaccine in uninfected individuals begins 14 days post-vaccination and reaches 50-80% between days 15-35) (2).”
BackgroundMethodParry, H., Bruton, R. K., Ayodele, M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4095379 · Cited by 4
Roubenoff, E., Feehan, D. M., & Mahmud, A. S. (2023) · Epidemics · doi:10.1016/j.epidem.2023.100686 · Cited by 3
Bekki, H., Arizono, T., Tagata, R., et al. (2021) · Cureus · doi:10.7759/cureus.14410 · Cited by 4
Delayed local reactions after the first administration of the ChAdOx1 nCoV‐19 vaccine
Shin, E., Bae, S., Jung, J., Song, W., Kwon, H., Kim, H., Kim, S., Kim, T., Cho, Y. S., & Lee, J. (2021) · Allergy · doi:10.1111/all.14978 · Cited by 4
Ahmed, N., Athavale, A., Tripathi, A. H., Subramaniam, A., Upadhyay, S. K., Pandey, A. K., Rai, R. C., & Awasthi, A. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13345 · Cited by 4
Solomadin, M., Tabynov, K., Petrovsky, N., & Tabynov, K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2258571 · Cited by 5
Carai, P., Ruozi, G., Paye, A., Debing, Y., Bortolotti, F., Lecomte, J., Zentilin, L., Jones, E. A. V., Giacca, M., & Heymans, S. R. B. (2022) · Scientific Reports · doi:10.1038/s41598-022-11131-w · Cited by 5
Coronavirus vaccination rates in cultural areas in Germany
Spahn, C., Hipp, A. M., Richter, B., & Nusseck, M. (2022) · Epidemiology and Infection · doi:10.1017/s0950268822000085 · Cited by 5
Luo, Y., Li, Q., Zhou, S., Oh, H., Jablonski, J., Song, Y., Su, Y., Wu, Y., Zhu, H., Ortega, J., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123754 · Cited by 7
COVID-19 vaccine-associated lymphadenopathy: a review
Ciliberti, V., Maffei, E., Giudice, V., Ciancia, G., Zeppa, P., & Caputo, A. (2024) · Infezioni in Medicina · doi:10.53854/liim-3202-1 · Cited by 5
Vaccine response in people with multiple sclerosis treated with fumarates
Tremblay, M. A., Vukusic, S., Shanmugasundaram, M., Božin, I., Levin, S. N., Gocke, A. R., & Wipfler, P. (2023) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173231191170 · Cited by 6
“at preventing symptomatic COVID-19, and nearly eliminated severe disease.(14,15) In a study of 317 pwMS, full vaccination against COVID-19 (n= 97) was associated with a significantly decreased risk of severe COVID-19 infection at a median of 5 months post-first vaccination compared with unvaccinated patients.”
BackgroundMerga, B. T., Ayana, G. M., Negash, B., Alemu, A., Abdurke, M., Abdu, A., Balis, B., Bekana, M., Fekadu, G., & Raru, T. B. (2022) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s361199 · Cited by 6
SARS-CoV2 and Anti-COVID-19 mRNA Vaccines: Is There a Plausible Mechanistic Link with Cancer?
Isidoro, C. (2025) · Cancers · doi:10.3390/cancers17233867 · Cited by 4
“Based on these considerations and on the results of the clinical trials claiming a relative (not absolute) 95% efficacy [57,58], the anti-COVID vaccination has been prioritized for cancer patients [65,67], neglecting the fact that those clinical trials did not include such a typology of patients…”
Du, Z., & Yin, J. (2022) · Allergologia et Immunopathologia · doi:10.15586/aei.v50i3.570 · Cited by 4
“2022;50(3):132–137 eISSN:1578-1267, pISSN:0301-0546”
MethodKashiwagi, K., Jimbo, K., Suzuki, M., Arai, N., Kudo, T., & Shimizu, T. (2022) · Vaccines · doi:10.3390/vaccines10101618 · Cited by 4
“Vaccination against SARS-CoV-2 is important for protection against SARS-CoV-2, and the first COVID-19 messenger RNA (mRNA) vaccine (Pfizer BioNTech: BNT162b2) was approved for those over 18 years of age in December 2020 [2].”
BackgroundSide Effects of Pfizer-BioNTech COVID-19 Vaccine among Libyan Young Adults: Observational Study
Shailabi, T. I. M., Borwis, E. O., Majeed, N. S., Bubtina, N. H., Betamar, N. M., & Abdeldaim, G. M. K. (2022) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2022.101005 · Cited by 4
Piquet, A. L., Corboy, J. R., & Vollmer, T. L. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211019567 · Cited by 4
Walton, M., Pletzer, V., Teunissen, T., Lumley, T., & Hanlon, T. (2023) · Drug Safety · doi:10.1007/s40264-023-01332-1 · Cited by 5
“The BNT162b2 vaccine demonstrated acceptable efficacy and safety in phase III clinical trials [2] and received provisional approval for use in adults aged 16 years and older from Medsafe, New Zealand’s Medicines and Medical Devices Safety Authority, on 3 February 2021 [3].”
Pflumm, D., Seidel, A., Klein, F. A. C., Groß, R. M., Krutzke, L., Kochanek, S., Kroschel, J., Münch, J., Stifter, K., & Schirmbeck, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1231274 · Cited by 5
Haase, M., Lesny, P., Haase‐Fielitz, A., et al. (2021) · Seminars in Dialysis · doi:10.1111/sdi.13043 · Cited by 4
“Vaccine side effects and reactions were assessed following the pivotal study by Polack et al.(8) Patients completed questionnaires independently or with the assistance of nursing staff to obtain information on the occurrence and duration of local and systemic side effects or the need to take medications or present to…”
MethodLi, J., & Foged, C. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2409142 · Cited by 6
RNA Viruses, Pregnancy and Vaccination: Emerging Lessons from COVID-19 and Ebola Virus Disease
Dhanya, C. R., Shailaja, A., Mary, A. S., Kandiyil, S. P., Savithri, A., Vishnu, S. K., Veettil, J. T., Vandanamthadathil, J. J., & Madhavan, M. (2022) · Pathogens · doi:10.3390/pathogens11070800 · Cited by 4
Genicio, A. A., García-Arqué, M. C., Gragea-Nocete, M., Llistosella, M., Moro-Casasola, V., Pérez-Díaz, C., Puigdellívol‐Sánchez, A., & Roca-Puig, R. (2025) · Vaccines · doi:10.3390/vaccines13090905 · Cited by 5
“On the other hand, the newly developed mRNA COVID-19 vaccines [13–16] also showed increased cardiovascular risk [17–20], but the benefits of vaccination in preventing severe COVID-19 outcomes have been considered to outweigh the potential complications [19].”
Cross, R. W., Wiethoff, C. M., Brown‐Augsburger, P., Berens, S. J., Blackbourne, J. L., Liu, L., Wu, X., Tetreault, J. W., Dodd, C., Ramtin, S., et al. (2023) · Pathogens · doi:10.3390/pathogens12121408 · Cited by 5
Schwarzer, R., Freys, S. D., Neuwinger, N., Beikert, N., Eberspächer, B., Edelmann, A., Żuchowski, M., Slothouwer, I., Stein, A., Theil, K., et al. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.532 · Cited by 4
“Especially the novel class of messenger RNA based vaccines showed promising efficacy in clinical trials.(3) Various vaccination schemes apply to the different vaccines.”
BackgroundTruong, L. B., Li, S., Domkofski, C., Lin, J., Co, C., Halwasia, S., Kuefner, M., Hu, Y., Mao, H., Wang, T.-H., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.028 · Cited by 8
Capacity of transportation and spread of COVID-19—an ironical fact for developed countries
Ma, L., Yu, Z., Jiao, Y., et al. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-12765-5 · Cited by 4
Bridging gene therapy and next-generation vaccine technologies
Bloom, K. M., Ely, A., Maepa, M. B., & Arbuthnot, P. B. (2024) · Gene Therapy · doi:10.1038/s41434-024-00502-9 · Cited by 4
Sun, T., Wang, Y., Song, X., Li, R., Mei, F., Yang, M., Huang, X., Li, Y., Zhou, X.-W., Wang, H., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02783-22 · Cited by 7
Matějková, N., Smělá, D., Beránek, M., et al. (2024) · Microchemical Journal · doi:10.1016/j.microc.2024.111554 · Cited by 4
Lee, J., Figueroa, A., Sachithanandham, J., Li, M., Connolly, C. M., Shapiro, J. R., Chen, Y., Jones, M., Dhara, V. G., Towns, M. C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1266370 · Cited by 4
Lionis, C. D., Petelos, E., Linardakis, M. K., Diamantakis, A., Symvoulakis, E. K., Karkana, M.-N., Kampa, M., Pirintsos, S., Sourvinos, G., & Castanas, E. (2023) · Diseases · doi:10.3390/diseases11030105 · Cited by 3
Regulatory issues and toxicological concerns related to nanocarriers
Kataki, M. S., Singh, J., Rajkumari, A., & Kakoti, B. B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24806-1.00027-3 · Cited by 5
Advancements in the Development of Anti-SARS-CoV-2 Therapeutics
Huang, J., Ma, Q., Su, Z., & Cheng, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910820 · Cited by 6
“The Pfizer (BNT162b2) and Moderna (mRNA-1273) vaccines have been reported to provide 95% and 94.1% protection, respectively, in clinical patients early in the onset of COVID-19 [52,53].”
BackgroundInfluentialSchirwani, N., Pateisky, P., Koren, T., Farr, A., Kiss, H., & Bancher‐Todesca, D. (2022) · Vaccines · doi:10.3390/vaccines10091505 · Cited by 4
Boldea, G.-J., Caragea, D. C., Nicolcescu, P., Pădureanu, V., Rădulescu, D., Boldea, A. M., Georgescu, I., & Georgescu, E. F. (2023) · Biomedical Reports · doi:10.3892/br.2023.1658 · Cited by 7
“By ensuring that medical staff and patients were vaccinated, the risk of transmitting the virus within medical institutions would have been substantially reduced (90).”
Advances in the structure-based design of protein vaccines for respiratory infectious diseases
Tie, X., Li, J., Wu, H., Weng, R., Zhang, Y., Li, J., & Chen, K. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.10.008 · Cited by 5
“During the COVID-19 pandemic, LNP-encapsulated mRNA vaccines such as BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna) were rapidly authorized and demonstrated high immunogenicity and large-scale manufacturing feasibility in clinical trials [78,79].”
Filippidis, P., Vionnet, J., Manuel, O., & Mombelli, M. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2013808 · Cited by 5
Coronavirus disease 2019 vaccination effectiveness based on the 2021 Japanese dialysis registry
Sugawara, Y., Iwagami, M., Kikuchi, K., et al. (2024) · Nephrology · doi:10.1111/nep.14366 · Cited by 4
Schiappacasse, G. (2021) · Current Oncology · doi:10.3390/curroncol28030186 · Cited by 5
“Furthermore, efficacy is similar in subgroup analyses defined by age, sex, race, ethnicity, baseline body mass index, and comorbidities; the safety of this vaccine is similar to other viral vaccines [6].”
BackgroundFassina, A., Fassan, M., Dosio, G. B., et al. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03020-w · Cited by 4
Earnest, L., Fernandez‐Ruiz, D., Edeling, M. A., Montoya, J. C., Yap, A. H. Y., Wong, C. Y., Holz, L. E., Gras, S., Collett, S., Cooney, J. P., et al. (2026) · npj Vaccines · doi:10.1038/s41541-025-01355-y · Cited by 4
Susac syndrome following COVID-19 vaccination: a case-based review
Fisher, L., David, P., Sobeh, T., Liberman, R. B., & Amital, H. (2023) · Clinical Rheumatology · doi:10.1007/s10067-023-06564-1 · Cited by 6
“Two messengers ribonucleic acid (mRNA) based, the BNT162b2—by BioNTech/Pfizer (Comirnaty®) and the mRNA-1273 by Moderna (SpikeVax®), were demonstrated to be highly effective in preventing mild-to-severe COVID-19 [1, 2].”
Method(2022) · doi:10.1101/2022.03.29.22273086 · Cited by 4
Vaccination anti COVID-19 pour les personnes souffrant de cancer : un impératif médical et éthique
Spano, J., Barré‐Sinoussi, F., Kiény, M. P., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.02.001 · Cited by 4
COVID-19 Vaccine in Children: Where Do We Stand?
Kumar, J., Meena, J. K., Kasi, S. G., & Shah, A. K. (2021) · Indian Pediatrics · doi:10.1007/s13312-021-2150-5 · Cited by 4
Al-Abdulla, O., & Kallström, A. (2023) · Medicine Conflict & Survival · doi:10.1080/13623699.2023.2198894 · Cited by 5
“On 11 March 2020, the World Health Organization (WHO) declared a coronavirus disease 2019 (COVID-19) pandemic (Polack et al. 2020).”
Background(2021) · doi:10.21203/rs.3.rs-505193/v1 · Cited by 391
A review on the COVID-19: Facts and current situation
Tiwari, U., Bano, A., & Khan, M. K. A. (2021) · NeuroPharmac Journal · doi:10.37881/1.616 · Cited by 4
The seven enigmas of SARS-CoV-2: From the past to the future
Andreakos, E., Arkin, L. M., Bastard, P., Bolze, A., Borghesi, A., Brodin, P., Casanova, J., Casari, G., Cobat, A., Drolet, B. A., et al. (2025) · Journal of Human Immunity · doi:10.70962/jhi.20250149 · Cited by 5
“Despite the efficacy of RNA vaccines (160, 177), the human genetic and immunological determinants of critical breakthrough cases remained unclear, especially in patients with normal antibody responses to the vaccine.”
A bibliometric analysis of the 100 most cited articles describing SARS-CoV-2 variants
Zhang, Y., Feng, M., He, Y., Liu, F., & Ma, R. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.966847 · Cited by 6
Puigdellívol‐Sánchez, A., Juanes-González, M., Calderón-Valdiviezo, A., Losa-Puig, H., González-Salvador, M., León-Pérez, M., Pueyo-Antón, L., Franco-Romero, M., Lozano-Paz, C., Borra, A. C., et al. (2025) · Healthcare · doi:10.3390/healthcare13111270 · Cited by 4
“COVID-19 vaccinations with Pfizer ® [18] and Moderna ® [19], began in 2021, starting with older people, while AstraZeneca ® [20] and Janssen ® [21] vaccines were administered to younger age groups.”
Investigating the tendency to use COVID-19 vaccine booster dose in Iran
Askarian, M., Kazerooni, A. R., Shayan, Z., Karimzadeh, P., Movahedi, M., & Hatam, N. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-09788-8 · Cited by 4
“Numerous articles have demonstrated the safety and cost-effectiveness of the vaccines [4, 5].”
BackgroundLozano‐Ojalvo, D., Cámara, C., López‐Granados, E., Nozal, P., Molina, L. D. P., Bravo‐Gallego, L. Y., Paz‐Artal, E., Pion, M., Correa‐Rocha, R., Ortíz, A., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3844997 · Cited by 4
Chua, J. X., Durrant, L. G., Chok, Y. L., & Lai, O. M. (2022) · iScience · doi:10.1016/j.isci.2022.105379 · Cited by 4
Marra, A., Kobayashi, T., Suzuki, H., Alsuhaibani, M., Schweizer, M. L., Diekema, D., Tofaneto, B. M., Bariani, L. M., Auler, M. D. A., Salinas, J., et al. (2022) · Antimicrobial Stewardship and Healthcare Epidemiology · doi:10.1017/ash.2021.261 · Cited by 4
A multi-country analysis of COVID-19 hospitalizations by vaccination status
Gonçalves, B. P., Jassat, W., Baruch, J., Hashmi, M., Rojek, A. M., Dasgupta, A., Martín‐Loeches, I., Reyes, L. F., Piubelli, C., Citarella, B. W., et al. (2023) · Med · doi:10.1016/j.medj.2023.08.005 · Cited by 4
Itamochi, M., Yazawa, S., Saga, Y., Shimada, T., Tamura, K., Maenishi, E., Isobe, J., Sasajima, H., Kawashiri, C., Tani, H., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-73004-8 · Cited by 5
“COVID-19 vaccines stimulate the production of neutralizing antibodies to SARS-CoV-2 in adults, although more recipients of COVID-19 mRNA vaccines reported adverse events (AEs) compared to placebo recipients 6 .”
BackgroundZelkoski, A. E., Goguet, E., Darcey, E. S., Alameh, M., Said, H., Pollett, S. D., Powers, J. H., Laing, E. D., Olsen, C. H., Mitre, E. E. S., et al. (2025) · Vaccines · doi:10.3390/vaccines13070718 · Cited by 6
Campagna, R., Mazzuti, L., Guerrizio, G., Nonne, C., Migliara, G., Vito, C. D., Mezzaroma, I., Chiaretti, S., Fimiani, C., Pistolesi, V., et al. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100246 · Cited by 4
“The clinical trial of BNT162b2 vaccine and along with other studies proved that protection against the symptomatic disease exerted by T cells starts about 10 days after the administration of the first dose, while high levels of neutralizing antibodies are only detectable 21 days after the first dose, emphasizing that…”
Sorcini, D., Falco, F. D., Gargaro, M., Bozza, S., Guarente, V., Cardinali, V., Stella, A., Adamo, F. M., Barcelos, E. C. S., Rompietti, C., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18602 · Cited by 5
So, H., Mok, C. C., & Yip, R. M.-L. (2021) · Journal of Clinical Rheumatology and Immunology · doi:10.1142/s2661341721400010 · Cited by 4
Juárez, I., Pérez-Flores, I., Meneses, A. A., López-Gomez, A., Romero, N. C., Cubillo, B. R., de la Higuera, M. Á. M., Jiménez, B. P., Gonzalez-Garcia, R., Amorós-Pérez, B., et al. (2025) · Vaccines · doi:10.3390/vaccines13020123 · Cited by 6
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.